Business, energy, technology, markets and global industry news from Business News Today

RNA editing

PharmaDeviceNews RNA editing
Therapeutic RNA editing recruits naturally occurring enzymes to rewrite individual RNA letters without permanently altering genomic DNA, offering a reversible alternative to permanent gene editing while potentially simplifying long-term risk management. Representative image.
Features & Analysis

ADAR versus CRISPR: why some genetic diseases may be better treated at the RNA level

Therapeutic RNA editing recruits naturally occurring enzymes to rewrite individual RNA letters without permanently changing genomic DNA, trading lifetime correction for reversibility and potentially simpler risk management.

Read More
Representative image: Advanced liver cancer imaging and RNA-based oncology research illustrate Rznomics Inc.’s FDA RMAT designation for RZ-001 in hepatocellular carcinoma, highlighting the growing role of RNA editing in next-generation cancer therapy.
Pharma & Biotech

FDA RMAT status puts Rznomics’ RNA editing platform under a brighter clinical spotlight

RNA editing just gained a liver cancer spotlight. Rznomics must now prove RZ-001 can turn early response signals into durable clinical value.

Read More
Pharma & Biotech

Can Rznomics turn RZ-001 into a breakthrough therapy for hepatocellular carcinoma?

Rznomics reported interim RZ-001 liver cancer data at AACR 2026. Read why the efficacy and safety signals could matter for hepatocellular carcinoma.

Read More